It is a randomized, observational and controlled non-blinded interventional cohort study, divided into two different phases of generation and validation of the screening program. From 5,500 patients, 100 will be randomly selected for the first phase of the project to create and apply a sequential screening program in a high-risk population by integrating clinical, electrocardiographic and biological information, testing of different pulse devices (MyDiagnostick, AliveCor and WatchBP) for AF screening, discovery of blood biomarkers for AF by aptamer technology, and validation of biological candidates from the literature and previous results. AF diagnosis will be based on detection in four-week Holter-EKG monitoring. In the second phase, the investigators will apply the best candidates in a sequential screening program in a high-risk population (aged 65-75 with hypertension and diabetes) by clinical variables and performing pulse device detection. Biomarkers will be measured in the negative cases to perform Holter-ECG monitoring in the highest-risk patients. In the final step of the study, cost-efficacy analyses will be carried out.